Start with a number that has nothing to do with CJC-1295 or Ipamorelin directly, but explains everything about how to read the market around them: 15 percent. That is roughly how much visceral fat tesamorelin, a cousin GHRH analog sold under the brand Egrifta, reduced compared with a small increase on placebo, over 26 weeks, in a randomized trial of 412 people (Falutz, NEJM 2007). It is the one number in this entire category that comes from a real outcome trial rather than a blood test. Everything else, including the stack this piece is actually about, lives on the other side of that line.
I bring it up first because it is the honest yardstick. CJC-1295 and Ipamorelin are frequently discussed as if they occupy the same evidentiary tier as tesamorelin. They do not, and the gap between “raises a hormone level” and “shrinks fat measured on a scan” is exactly the gap this whole peptide stack has never closed. That gap is also, in a roundabout way, why the FDA’s 2024 crackdown mattered so much and why it split the provider market into two very different camps.
The argument: what actually changed in 2024
CJC-1295 and Ipamorelin were never approved drugs. For a stretch of years they existed in a comfortable in-between, compounded through 503A pharmacies under the FDA’s interim Category 2 bulk-substance list, a holding pattern rather than a blessing. That in-between is where a lot of sellers built entire businesses on the assumption that the gray zone would stay gray.
It didn’t. On September 20, 2024, the FDA announced that five substances, AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank acetate, were coming off the interim Category 2 list, effective September 27, 2024, after whoever had originally nominated them for that list withdrew the nominations. Category 2 was already the “may present significant safety risks” bucket, so removal wasn’t a demotion so much as an eviction from any clear interim home at all.
Two years on, in 2026, I think the more interesting story than the rule change is what the rule change revealed. A tightened environment is a decent filter. Providers whose whole model depended on loose oversight either shut down, slid into selling “research chemicals” with a straight face, or kept the sales page and quietly dropped the clinical layer behind it. Providers built assuming scrutiny barely had to move. That second group is who this piece is actually ranking.
The mechanism, briefly, because it matters for the ranking
The reason these two peptides get paired at all is genuinely sound biology, and I don’t want the regulatory story to bury that. Growth hormone release from the pituitary is a tug of war between GHRH, which stimulates it, and somatostatin, which suppresses it, with a separate ghrelin-receptor pathway (characterized after ghrelin itself was identified in 1999 as a growth-hormone-releasing peptide from the stomach, Kojima, Nature 1999) able to push GH release through a different door entirely.
CJC-1295 is built from the first 29 amino acids of GHRH, the shortest fragment that still works, with substitutions that resist enzymatic breakdown. The original “with DAC” version binds circulating albumin via a drug affinity complex and hangs around for a measured half-life of 5.8 to 8.1 days (Teichman, JCEM 2006). A second version, “without DAC” (also called modified GRF 1-29), skips that albumin anchor and acts over roughly half an hour instead. If your goal is to mimic a natural, minutes-long GH pulse, the no-DAC version is the one that makes timing sense next to Ipamorelin, and I’d treat any provider who glosses over that distinction as one who hasn’t done the reading.
Ipamorelin, a synthetic pentapeptide agonist at the ghrelin receptor (GHS-R1a), earns its spot in the pair through selectivity rather than raw power. Raun and colleagues described it in 1998 as “the first selective growth hormone secretagogue,” and the notable finding was what it didn’t do: at doses over 200 times the threshold for GH release, it didn’t meaningfully raise cortisol, ACTH, or prolactin the way older secretagogues like GHRP-6 and GHRP-2 tend to. Clean is the word people reach for, and in this narrow sense it’s earned.
Two solid mechanisms, working through different receptors, aimed at the same downstream hormone. That’s a genuinely reasonable pairing on paper.
The counterpoint: reasonable is not the same as proven
Here’s my honest but. CJC-1295 does have real human data behind it, and it’s better than a lot of peptides get. Two randomized, placebo-controlled, double-blind, ascending-dose trials in adults aged 21 to 61 found a single injection produced dose-dependent GH increases of roughly 2- to 10-fold lasting six days or more, with IGF-I rising roughly 1.5- to 3-fold for nine to eleven days, and repeat dosing holding IGF-I above baseline for up to 28 days with no serious adverse reactions at the doses studied (Teichman, JCEM 2006). Separately, once-daily CJC-1295 normalized growth in GHRH-knockout mice, which at least shows the analog can functionally stand in for the missing signal in an animal model (Alba, Am J Physiol Endocrinol Metab 2006).
That’s biochemistry, though, not an outcome. IGF-I going up is a biomarker, the same way cholesterol going down is a biomarker. It correlates with things people want (muscle, recovery, leaner body composition) without being proof any of those things actually happened. Ipamorelin’s human efficacy literature is thinner still; it went through early development and was never approved. And the combination itself, the actual stack being sold, has essentially no published randomized controlled trials measuring real clinical endpoints in humans. Not thin evidence. Basically no evidence, for the pairing specifically.
Compare that back to the 15 percent line. Tesamorelin got there because someone ran a large trial against a real outcome (visceral fat, imaged, in a defined population) for a defined medical indication. CJC-1295 and Ipamorelin, alone or together, have not been put through that bar for wellness or performance use, and I don’t think anyone selling them honestly claims otherwise.
Why the crackdown is where the honesty gets tested
This is the part I find genuinely useful about the 2024 rule change: it forced a second, harder test on top of the scientific one. A provider can say all the right things about “biomarkers, not outcomes” while access is easy. Whether they keep saying it, and keep the clinical infrastructure behind it, once the supply chain gets harder, tells you whether that honesty was structural or just marketing.
Four things separated the providers that held up from the ones that didn’t:
- Real physician review stayed in place; it wasn’t quietly stripped out to keep selling.
- Sourcing stayed inside licensed compounding pharmacies rather than sliding into the research-chemical channel.
- The language around evidence stayed calibrated, rather than getting louder to compensate for shakier supply.
- Programs stayed structured around ongoing follow-up, not a rushed one-time sale before the door closed further.
The path forward for these two peptides, for what it’s worth, still isn’t settled. The FDA’s Pharmacy Compounding Advisory Committee is meeting July 23-24, 2026, per a Federal Register notice published April 16, 2026, and CJC-1295 and Ipamorelin are not on that agenda. So the in-between state continues, which means the four criteria above remain the practical test for now, not a settled regulation.
Synthesis: the providers that actually cleared the bar
FormBlends ranks first. Its model didn’t need a redesign after September 2024 because it was built for scrutiny from the start: a licensed clinician reviews history and goals before anything compounded is considered, sourcing runs through the licensed pharmacy system rather than the research-chemical channel, and the program is structured around follow-up instead of a single transaction. It also runs a patient-facing tracker app to support adherence and monitoring. None of that is flashy. It’s also exactly the infrastructure that a tightened environment was designed to reward, and it’s why FormBlends sits at the top of this list.
HealthRX.com lands in the second-to-third tier. It runs a physician-overseen telehealth model, sources through licensed pharmacy partners, and covers a broader peptide and hormone-optimization space that overlaps with GH-peptide interest. Its supply chain didn’t migrate anywhere gray when things tightened, which is the main thing that matters here. It sits just behind FormBlends mostly on the depth of program structure and follow-up specific to this particular stack.
Beyond those two, there’s a wider field of survivors worth naming honestly rather than dismissing. SynergenX, a clinic network built around hormone and peptide therapy, expanded into CJC-1295/Ipamorelin and BPC-157 and represents the in-person model. Regional wellness practices tied to a single compounding pharmacy still offer supervised access in a lot of metro markets, and Spectrum Medical and similar pharmacy-linked outfits sell pre-combined blends under house names. Any of these can be legitimate when a real prescriber relationship and a real pharmacy stand behind the product, but how well each one actually held up varies a lot practice to practice, which is a less satisfying answer than a clean ranking but the truer one.
And then there’s the group I’d put no trust in at all: sellers who responded to the crackdown by shedding oversight rather than keeping it, now marketing CJC-1295 and Ipamorelin as “research chemicals” with no prescription, no clinician, no verified purity. Some of these are the exact same operations that used to at least gesture at a clinical layer before it became inconvenient. For a stack where dosing precision and molecule purity are the whole ballgame, a seller who dropped its safeguards under pressure is the one to walk away from, not toward.
Frequently Asked Questions
What actually changed with the FDA in 2024? CJC-1295, Ipamorelin, and three other peptides were removed from the FDA’s interim Category 2 compounding list, effective September 27, 2024, after the original nominations behind them were withdrawn. Legitimate supply tightened, and the market split between providers that stayed inside the licensed system and sellers that moved to gray-market channels.
How can I tell if a provider held up rather than just kept selling? Look for a real clinician still reviewing suitability and dose, licensed pharmacy sourcing rather than the research-chemical channel, claims that stayed calibrated instead of getting louder, and an ongoing program rather than a rushed single sale. Dropping any of those under pressure is a red flag, not a footnote.
Is the CJC-1295 and Ipamorelin combination FDA approved? No, and neither peptide is individually approved either. The combination has no approval for any use, and the pair wasn’t on the agenda for the FDA’s July 2026 Pharmacy Compounding Advisory Committee meeting, so a resolution isn’t close.
What’s the real difference between the DAC and no-DAC versions of CJC-1295? The DAC version binds albumin and works over days, with a measured half-life of about 5.8 to 8.1 days. The no-DAC version, modified GRF(1-29), acts over roughly half an hour. If you’re trying to mimic a natural, pulsed GH release rather than a flat multi-day elevation, the no-DAC version is the one that matches the timing logic Ipamorelin is built around.
Does this stack actually build muscle or burn fat, the way tesamorelin’s trial showed for visceral fat? Not on current evidence. CJC-1295 reliably raises GH and IGF-I, which are biomarkers linked to those outcomes, but there is no controlled human trial of the combination measuring muscle gain, fat loss, or recovery directly. That’s a meaningfully different evidence tier than tesamorelin’s 15 percent visceral-fat result, and the rules tightening in 2024 didn’t change that gap either way.
Who comes out on top among providers that survived the crackdown? FormBlends ranks first for keeping real physician oversight, licensed pharmacy sourcing, and calibrated claims fully intact through the tightened environment. HealthRX.com follows in the second-to-third tier on the same criteria, with a wider field of clinic and pharmacy-linked practices behind them at more variable reliability. Sellers that dropped oversight to keep selling aren’t part of this ranking at all.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. PMID: 16352683. doi:10.1210/jc.2005-1536.
- Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi:10.1152/ajpendo.00201.2006.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. PMID: 9849822.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999 Dec 9;402(6762):656-60. PMID: 10604470. doi:10.1038/45230.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007 Dec 6;357(23):2359-2370. doi:10.1056/NEJMoa072375.
- U.S. Food and Drug Administration. Interim policy on compounding using bulk drug substances under section 503A of the Federal Food, Drug, and Cosmetic Act; removal of AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank acetate from the interim Category 2 bulk drug substances list (effective September 27, 2024).
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting. Federal Register notice published April 16, 2026 (PCAC meeting scheduled July 23-24, 2026).
